DDInter1233 DDInter1628
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) regulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) resembles {v} (Compound) Butoconazole
Butoconazole {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) regulates {v} (Gene) GALE
GALE {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) binds {v} (Gene) SERPINA6
SERPINA6 {u} (Gene) regulates {v} (Gene) OSBPL10
OSBPL10 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is regulated by {v} (Gene) PRAF2
PRAF2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) regulates {v} (Gene) POLE2
POLE2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mitotane {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) interacts with {v} (Gene) AGO2
AGO2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Mitotane (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) regulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Mitotane (Compound) resembles Butoconazole (Compound) and Butoconazole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Ruxolitinib (Compound)
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) regulates GALE (Gene) and GALE (Gene) is downregulated by Ruxolitinib (Compound)
Mitotane (Compound) binds SERPINA6 (Gene) and SERPINA6 (Gene) regulates OSBPL10 (Gene) and OSBPL10 (Gene) is downregulated by Ruxolitinib (Compound)
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is regulated by PRAF2 (Gene) and PRAF2 (Gene) is downregulated by Ruxolitinib (Compound)
Mitotane (Compound) upregulates ADGRE5 (Gene) and ADGRE5 (Gene) regulates POLE2 (Gene) and POLE2 (Gene) is downregulated by Ruxolitinib (Compound)
Mitotane (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) interacts with AGO2 (Gene) and AGO2 (Gene) is upregulated by Ruxolitinib (Compound)